[CAS NO. 382180-17-8] Pyroxamide
PRODUCTS SPECIFICATIONS [382180-17-8]
DESCRIPTION [382180-17-8]
Overview
| MDL | MFCD13194970 |
|---|---|
| Molecular Weight | 265.31 |
| Molecular Formula | C13H19N3O3 |
| SMILES | O=C(NO)CCCCCCC(NC1=CC=CN=C1)=O |
3 Publications Citing Use of MCE
Summary
IC50 & Target
|
HDAC1 100 nM (ID 50 ) |
In Vitro
Pyroxamide (1.25-20.0 μM; 24-72 hours) suppresses RD and RH30B cells growth, pyroxamide resulted in 44% dead cells for 72 h at 20.0 μM, results in 86% dead cells in culture
[1]
.
Pyroxamide (10.0-20.0 μM; 48 hours) shows sub-G1 fractions of 45.0% and 72.3% at 10.0 and 20.0 μM, respectively
[1]
.
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Cell Viability Assay [2]
| Cell Line: | RD cells; RH30B cells |
| Concentration: | 1.25-20.0 μM |
| Incubation Time: | 24 hours; 48 hours; 72 hours |
| Result: | Resulted in a cell growth decrease in RD and RH30B cells. |
Cell Cycle Analysis [2]
| Cell Line: | RD cells; RH30B cells |
| Concentration: | 10.0 μM; 20.0 μM |
| Incubation Time: | 48 hours |
| Result: | Increased the sub-G1 fractions at 48 hours compared with control samples. |
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date | Phase |
|---|---|---|---|---|
| NCT00042900 | Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI) |
Chronic Myeloproliferative Disorders|Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic Syndromes|Precancerous Condition|Small Intestine Cancer|Unspecified Adult Solid Tumor, Protocol Specific
|
April 2002 | Phase 1 |
Appearance
Solid
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
| Powder | -20°C | 3 years |
|---|---|---|
| 4°C | 2 years | |
| In solvent | -80°C | 6 months |
| -20°C | 1 month |
Solvent & Solubility
DMSO : 125 mg/mL ( 471.15 mM ; Need ultrasonic)
Stock Solutions
| Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
|---|
| 1 mM | 3.7692 mL | 18.8459 mL | 37.6918 mL |
| 5 mM | 0.7538 mL | 3.7692 mL | 7.5384 mL |
| 10 mM | 0.3769 mL | 1.8846 mL | 3.7692 mL |
References
- [1] Butler LM, et al. Inhibition of transformed cell growth and induction of cellular differentiation by pyroxamide, an inhibitor of histone deacetylase. Clin Cancer Res. 2001 Apr;7(4):962-70.
- [2] Kutko MC, et al. Histone deacetylase inhibitors induce growth suppression and cell death in human rhabdomyosarcoma in vitro.Clin Cancer Res. 2003 Nov 15;9(15):5749-55.
